Vernalis plc (LON:VER)‘s stock had its “buy” rating reiterated by equities researchers at RX Securities in a report issued on Monday.

Several other equities research analysts also recently weighed in on the stock. Panmure Gordon downgraded shares of Vernalis plc to a “hold” rating and set a GBX 65 ($0.86) price target for the company. in a research note on Friday, April 21st. Numis Securities Ltd reaffirmed an “add” rating and issued a GBX 29 ($0.38) price target on shares of Vernalis plc in a research note on Friday, April 21st. N+1 Singer reaffirmed a “hold” rating and issued a GBX 28 ($0.37) price target on shares of Vernalis plc in a research note on Friday, April 21st. Finally, Stifel Nicolaus decreased their price target on shares of Vernalis plc from GBX 29 ($0.38) to GBX 24 ($0.32) and set a “hold” rating for the company in a research note on Friday, April 21st. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of GBX 39.40 ($0.52).

Shares of Vernalis plc (VER) traded down 10.53% during trading on Monday, reaching GBX 17.00. 143,567 shares of the company were exchanged. The firm’s market cap is GBX 89.48 million. Vernalis plc has a 52-week low of GBX 16.00 and a 52-week high of GBX 49.75. The stock’s 50-day moving average is GBX 18.15 and its 200-day moving average is GBX 22.70.

WARNING: “RX Securities Reaffirms Buy Rating for Vernalis plc (LON:VER)” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/07/rx-securities-reaffirms-buy-rating-for-vernalis-plc-lonver.html.

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Analyst Recommendations for Vernalis plc (LON:VER)

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.